Active	Status	Sponsor type	Region	Phase	Filter
1 Active 19 Inactive 20 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   - « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   Show only changed items Enrollment:

Advanced Filters

1 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
timbetasin ophthalmic (RGN-259) / ReGenTree
NCT05555589: Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2	Recruiting	3	70	US	RGN-259, Tβ4, Thymosin Beta 4, Timbetasin, Placebo, Vehicle Control	ReGenTree, LLC	Neurotrophic Keratopathy	07/24	11/24
timbetasin topical (RGN-137) / RegeneRx
No trials found

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
timbetasin ophthalmic (RGN-259) / ReGenTree
NCT05555589: Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2	Recruiting	3	70	US	RGN-259, Tβ4, Thymosin Beta 4, Timbetasin, Placebo, Vehicle Control	ReGenTree, LLC	Neurotrophic Keratopathy	07/24	11/24
timbetasin topical (RGN-137) / RegeneRx
No trials found